Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice fella - nice
A little premature but if anyone wants to know why I bought this stick, just follow the link in the signature.
"CBAY Lot Details as of 07:22 PM ET, 04/09/2020"
"Open Date","Quantity","Price","Cost/Share","Market Value","Cost Basis","Gain/Loss $","Gain/Loss %","Holding Period",
"03/19/2020 09:40:23","3,007","$1.69","$1.26","$5,081.83","$3,788.82","$1,293.01","+34.13%","Short Term",
"03/19/2020 09:37:38","1,000","$1.69","$1.26","$1,690.00","$1,260.00","$430.00","+34.13%","Short Term",
"03/19/2020 09:36:58","993","$1.69","$1.26","$1,678.17","$1,251.18","$426.99","+34.13%","Short Term",
"03/17/2020 16:00:13","81","$1.69","$1.31","$136.89","$106.11","$30.78","+29.01%","Short Term",
"03/17/2020 15:59:53","1,125","$1.69","$1.31","$1,901.25","$1,473.75","$427.50","+29.01%","Short Term",
"02/27/2020 12:54:36","9,675","$1.69","$1.65","$16,350.75","$15,921.18","$429.57","+2.7%","Short Term",
"02/27/2020 12:54:36","200","$1.69","$1.64","$338.00","$328.00","$10.00","+3.05%","Short Term",
"02/27/2020 11:53:58","125","$1.69","$1.57","$211.25","$196.25","$15.00","+7.64%","Short Term",
"Total","16,206","--","--","$27,388.14","$24,325.29","$3,062.85","+12.59%","--",
Picked up 10,000 shares at $1.64 last week. Looking for $3-$5 per share in the coming months.
* * $CBAY Video Chart 02-12-2020 * *
Link to Video - click here to watch the technical chart video
* * $CBAY Video Chart 01-30-2020 * *
Link to Video - click here to watch the technical chart video
* * $CBAY Video Chart 12-13-2019 * *
Link to Video - click here to watch the technical chart video
Yep. I was able t ok add at $2.06... headed up.now.
LMFAO... again!!! What happened????? I thought you guys have money to sell anything down!!!! The butterfly always thinks itself a bird. Being dumb is a terrible disease
I kept seeing them from AH yesterday to premkt today and I said these high schoolers are about to be taught a bad lesson...lol
Loaded this at $1.33 and $1.37. I posted about it yesterday and expected IDIOTS to come.and lower it. They did and I added at $1.54. See you at $2.25 in a week!!!
* * $CBAY Video Chart 11-26-2019 * *
Link to Video - click here to watch the technical chart video
Nice $0.20 here today. It may test $1.80 tomorrow for my exit
Analyst with an average price target of $10...CBAY
* * $CBAY Video Chart 11-25-2019 * *
Link to Video - click here to watch the technical chart video
* * $CBAY Video Chart 06-18-2019 * *
Link to Video - click here to watch the technical chart video
News: $CBAY CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
NEWARK, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced FDA clearance of the company’...
Read the whole news https://marketwirenews.com/news-releases/cymabay-therapeutics-announces-ind-to-commence-a-clinical-study-of-seladelpar-to-treat-primary-sclerosing-cholangitis-8373898.html
Ah I forgot you are just looking at numerology and don’t need to know anything at all about the company.
Do you think Perelman watches you videos?
* * $CBAY Video Chart 06-12-2019 * *
Link to Video - click here to watch the technical chart video
* * $CBAY Video Chart 06-11-2019 * *
Link to Video - click here to watch the technical chart video
* * $CBAY Video Chart 11-13-18 * *
Link to Video - click here to watch the technical chart video
Latebreaker oral presentation on interim data October 23
Cantor Fitzgerald initiates a strong buy with a PT of $16
Could u alert me next time :/
Difference between trading vs long term biotech investing based on DD. Up 300%+
Oh no I held on from a major down p/l loss from yesterday and made it out with a smaller loss I could of actually made profit but considering waking up to see money I could of bought a car with vanish I'm still lucky to make it out
I am out with a big loss yesterday, and wait for dust settled. Data looks very promising but still in phase2. Will watch for phase3 trial progress and data.
* * $CBAY Video Chart 07-18-17 * *
Link to Video - click here to watch the technical chart video
This stock trading backwards this was suppose happen yesterday and yesterday was suppose to happen today
Hey I got my butt slapped by this one unbelievable day MM driving this one imo
This stock is heavily manipulated and it will likely go down tomorrow. I lost my shirt here
Amazing there was so much sell pressure.
* * $CBAY Video Chart 07-17-17 * *
Link to Video - click here to watch the technical chart video
Yep short about to get burned $CBAY
Today's news is pretty good and SP should be higher. Hope shorts start to cover soon
The poster does not appear to contain any not previously disclosed information. As such not material and hence no need to PR.
CBAY releases poster presented at EASL
http://content.equisolve.net/cymabay/media/c0fe3312e49227e646be42d854c9d5bc.pdf
Posted on their website........why no PR??
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
346
|
Created
|
04/05/14
|
Type
|
Free
|
Moderators |
CymaBay is a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the lead product candidate, possesses two therapeutic actions in a single drug: in gout patients it is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease. Arhalofenate’s differentiated profile is intended for use in a large population, with significant advantages over marketed and emerging agents which have limitations in their efficacy, tolerability, and use in patients with common comorbidities. The Company is poised to follow arhalofenate with two additional clinical stage product candidates, one in diabetes and one in mixed dyslipidemia.
Our pipeline includes three clinical stage programs. Across this portfolio, a total of 23 clinical studies, including eleven Phase 2 studies, have been completed.
Partner | Program | Research | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|
Arhalofenate | Gout | |||||
MBX-8025 | High Unmet Need / Orphan Disease | |||||
MBX-2982 | Diabetes |
CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560
Sujal Shah
(917) 877-2194
investors@cymabay.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |